Dexmedetomidine
Conditions
Keywords
dexmedetomidine, mannitol
Brief summary
Dexmedetomidine is a potent alpha-2 adrenergic receptor agonist. In addition, dexmedetomidine-induced stimulation of the postsynaptic alpha-2 adrenergic receptor on the cerebral blood vessels can cause cerebral vasoconstriction and decrease cerebral blood flow
Interventions
DRUGDexmedetomidine with Mannitol
receive 1 mcg/kg of dexmedetomidine added to 0.4 mcg/kg of mannitol
DRUGMannitol (20%)
receive 0.5 g/kg of mannitol
Sponsors
Cairo University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
40 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
ASA I-II Patients scheduled for elective robot-assisted laparoscopic prostatectomy
Exclusion criteria
* • ASA physical status \> II * Cardiac patients * Cerebrovascular disease * Glaucoma * Hepatic failure * Renal failure * History of anaphylactic reaction to dexmedetomidine or mannitol * Hemodynamic instability * Cannot measure ONSD for example due to ophthalmological problems. * Any cause of preoperative increase in ICP for example intracranial space occupying lesions.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| optic nerve sheath diameter | 90 minutes |
Secondary
| Measure | Time frame |
|---|---|
| Postoperative neurologic complications | 24 HOURS |
| Postoperative cardiac complications | 24 hours |
| Duration of hospital stay | 30 days |
Countries
Egypt
Outcome results
None listed